By Cecilia Butini 
 

Bayer AG said Wednesday that the U.S. Food and Drug Administration has granted approval to its heart-failure drug Vericiguat, also known by its brand name Verquvo.

The German chemical and pharmaceutical conglomerate said the drug was developed jointly with Merck Sharp & Dohme Corp., which retains commercial rights to Vericiguat in the U.S. Bayer has exclusive commercial rights in the rest of the world, the company said.

The FDA approval was granted on the basis of results from the pivotal phase 3 Victoria clinical trial and follows priority review designation from the U.S. agency.

The drug is indicated to reduce the risk of cardiovascular death and heart failure hospitalization in adults with symptomatic chronic heart failure, Bayer said.

It has been submitted for marketing authorization in the European Union, Japan, China and other countries world-wide, Bayer said.

 

Write to Cecilia Butini at cecilia.butini@wsj.com

 

(END) Dow Jones Newswires

January 20, 2021 07:11 ET (12:11 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Bayer (XE:BAYN)
Historical Stock Chart
From Sep 2021 to Oct 2021 Click Here for more Bayer Charts.
Bayer (XE:BAYN)
Historical Stock Chart
From Oct 2020 to Oct 2021 Click Here for more Bayer Charts.